Immediate Impact

1 from Science/Nature 71 standout
Sub-graph 1 of 19

Citing Papers

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
Pancreatic cancer: Advances and challenges
2023 Standout
15 intermediate papers

Works of J. Peter being referenced

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus
2011
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
2009

Author Peers

Author Last Decade Papers Cites
J. Peter 681 407 625 12 923
Ann Michelini 708 384 493 15 983
Riley Fadden 696 186 231 19 890
R H Reznek 545 105 433 23 1.1k
Raphael Levey 202 215 135 15 899
Valentine Jehl 789 522 720 23 1.1k
Sui Zee 917 191 518 14 1.2k
P SWALSKY 713 59 186 13 914
Laura Tang 481 347 507 15 768
Alejandra Flores-Chávez 703 63 107 14 1.2k
A. Loverre 465 44 194 7 885

All Works

Loading papers...

Rankless by CCL
2026